NDAORALTABLETPriority Review
Approved
May 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
Priority Review
CYTOMEL (liothyronine sodium) by Pfizer is synthesis. Approved for multiple sclerosis. First approved in 1956.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYTOMEL (liothyronine sodium) is a synthetic thyroid hormone (T3) that binds to thyroid receptors in cell nuclei to activate gene transcription and protein synthesis. It is indicated for multiple sclerosis and functions as a direct replacement or supplementation of endogenous T3, with approximately 80% of physiological thyroid hormone activity derived from peripheral conversion of T4 to T3. This oral tablet formulation has been a foundational endocrine therapy since 1956.
$2MPart D
LOE ApproachingWith only $2M in Part D spending and LOE approaching, this is a legacy asset with minimal commercial expansion opportunity and likely a small, maintenance-focused team.
Mechanism of Action
synthesis. Triiodothyronine (T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid…
Worked on CYTOMEL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.